Skip to main content
. 2022 Dec 1;6:e2200263. doi: 10.1200/PO.22.00263

FIG 2.

FIG 2.

Seribantumab clinical activity in a patient with KRAS wt PDAC harboring an ATP1B1-NRG1 fusion. Plot of CA19-9 tumor marker (blue line) and sum of target lesions (red line). Dot represents time point of measurement. ATP1B1, ATPase Na+/K+ transporting subunit beta 1; CA 19-9, carbohydrate antigen 19-9; KRAS, Kirsten rat sarcoma; NRG1, neuregulin-1; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; SD, stable disease; wt, wild-type.